The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck Serono
 
Consulting or Advisory Role - Amgen; Merck; Roche
Travel, Accommodations, Expenses - Amgen
Identification of FAS Gene Mutations in Adult T-Cell Leukemia/Lymphoma (ATL) and HTLV-I Associated Myelopathy (HAM/TSP).
 
Timothy Jay Price
No Relationships to Disclose
 
Lin Shen
No Relationships to Disclose
 
Brigette Ma
Honoraria - Merck Serono; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Merck Serono; Merck Sharp & Dohme; Novartis
Research Funding - Novartis
Travel, Accommodations, Expenses - Amgen
 
Regina Esser
Employment - Merck KGaA
 
Wen-Feng Chen
No Relationships to Disclose
 
Peter Gibbs
Honoraria - Amgen; Merck; Roche; SERVIER; Sirtex Medical
Research Funding - Amgen (Inst); Merck Serono (Inst); Roche (Inst); Ventana Medical Systems (Inst)
 
Robert S.C. Lim
Honoraria - Roche; Sanofi
Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
 
Ann-Lii Cheng
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Serono; Novartis; Ono Pharmaceutical; ONXEO
Speakers' Bureau - Novartis
Research Funding - Sanofi